semaglutide covered by medi cal GLP-1 for Weight Loss Semaglutide vs Tirzepatide: Effectiveness, Side

Semaglutide Label Update Supported by EMA On December 12, Novo Nordisk announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion on updating the label for its blockbuster therapy Ozempic (semaglutide) to include information on reducing the risk of kidney-related events

14 months: Weight regain slows and plateaus at approximately 75% of the original weight loss

In the STEP 1 trial (published in the New England Journal of Medicine), participants using Wegovy lost an average of 14.9% of their body weight over 68 weeks approximately 35 lbs from a starting weight of 232 lbs

The Significance of Medical Supervision in Semaglutide Treatment Using semaglutide for weight loss needs careful medical watch to keep it safe and effective

Blasco BV, Garca-Jimnez J, Bodoano I, et al

K., et al